EMA sees fee income reduced by 8 million Euros
This article was originally published in SRA
Executive Summary
The European Medicines Agency is facing a drop of 8 million euros in estimated revenue from industry fees this year as a result of changes to the parameters used to calculate fee income1. At the same time, it is facing a constantly growing workload including a rise in the number of initial drug approval applications this year, driven mainly by an increase in orphan drug filings.